Long-term use of anti-anxiety drugs continues in B.C. despite known health risks

Published online in the journal Health Policy, the study by researchers at UBC's Centre for Health Services and Policy Research (CHSPR) is the first of its kind to examine the use of benzodiazepines such as Xanax and Ativan for an entire population over time. It's also the first to pinpoint the socio-economic characteristics associated with long-term users of such drugs.

Results show that seniors and low-income earners are more likely to be long-term users of benzodiazepines, with rates remaining steady over a 10-year period. Meanwhile, use among the middle-aged population has increased. Harms associated with long-term use (more than 100 days in a year) can include dependence and tolerance, cognitive impairment, and increased risks of falls in the elderly.

“Given the potential for dependence and harms associated with these drugs, they are recommended to be used sparingly for short periods,” says Colleen Cunningham, CHSPR researcher and lead author of the study. “However, our study suggests that a significant number of British Columbians – especially the elderly who suffer greater health risks from falls – are using them for long periods.”

Benzodiazepines are one of the most commonly prescribed types of neurological drugs in developed countries. The UBC study compared health records of B.C. residents from 1996 and 2006. Of the 4.9 per cent of the overall B.C. population who were given short-term benzodiazepine prescriptions in 2006 and 3.5 per cent who were given long-term prescriptions:

– Nearly half of long-term users were over age 65, and more than a quarter were 75 or older
– Two out of three were women, both for short- and long-term use
– Long-term users were more likely to be in the lowest income bracket than short-term or non-users

Cunningham and co-authors Gillian Hanley and Steve Morgan found long-term use in 2006 was associated with early use – half of all 2006 long-term users had been prescribed benzodiazepines in 1996. The researchers are calling for prescribing practices and policies that target populations younger than conventionally studied (i.e. under age 65) to reduce rates of long-term use.

This study was funded by the Canadian Institutes of Health Research.

The UBC Centre for Health Services and Policy Research (CHSPR) is part of the UBC School of Population and Public Health in the Faculty of Medicine. The Centre is committed to making lasting advances to population health and health services in Canada as leaders of independent, policy relevant research, graduate training and data resources.

Media Contact

Brian Lin EurekAlert!

All latest news from the category: Studies and Analyses

innovations-report maintains a wealth of in-depth studies and analyses from a variety of subject areas including business and finance, medicine and pharmacology, ecology and the environment, energy, communications and media, transportation, work, family and leisure.

Back to home

Comments (0)

Write a comment

Newest articles

Innovative 3D printed scaffolds offer new hope for bone healing

Researchers at the Institute for Bioengineering of Catalonia have developed novel 3D printed PLA-CaP scaffolds that promote blood vessel formation, ensuring better healing and regeneration of bone tissue. Bone is…

The surprising role of gut infection in Alzheimer’s disease

ASU- and Banner Alzheimer’s Institute-led study implicates link between a common virus and the disease, which travels from the gut to the brain and may be a target for antiviral…

Molecular gardening: New enzymes discovered for protein modification pruning

How deubiquitinases USP53 and USP54 cleave long polyubiquitin chains and how the former is linked to liver disease in children. Deubiquitinases (DUBs) are enzymes used by cells to trim protein…